Associations between endothelial nitric oxide synthase A/B, angiotensin converting enzyme I/D and serotonin transporter L/S gene polymorphisms with pulmonary hypertension in COPD patients
- 339 Downloads
Different biochemical pathways and cellular mechanisms play role in the pathogenesis of pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD). Alveolar hypoxia is not the only determinant of vascular remodeling, genetic factors are thought to have additive effects. We aimed to investigate the effects of endothelial nitric oxide synthase (eNOS A/B), angiotensin converting enzyme (ACE I/D) and serotonin transporter (5-HTT L/S) gene polymorphisms on development and severity of PH in COPD patients. 50 COPD patients without PH (group 1); 30 COPD patients with PH confirmed with echocardiography (group 2) and 49 healthy subjects (group 3) as control group were included to the study. eNOS A/B, ACE I/D and 5-HTT L/S gene polymorphisms and allele frequencies of COPD patients with and without PH and healthy subjects were determined. Functional parameters and echocardiographic measurements were recorded. Patients with PH were also assessed in two subgroups according to the severity of pulmonary arterial pressure (PAP). Significant differences among three groups in the distribution of 5-HTT genotype and allele frequency were present (respectively p = 0.002; p = 0.021). In group 2, LL and LS genotype rate was 93.3 % with a frequency of 71.2 % L allele and 28.3 % of S allele. 5-HTT LL genotype was present in 88.9 % of patients with PAP ≥50 mmHg significantly (p = 0.012). Other genotype distributions were not significantly different between two subgroups. The results of this study can suggest that COPD patients with L allele of 5-HTT may have higher risk for the development of PH and patients with LL genotype of 5-HTT may present higher PAP. We also demonstrated that eNOS and ACE gene polymorphisms were not associated with the development and severity of PH in our study population. Further studies with larger numbers of patients are needed to explore these relationships.
KeywordsCOPD eNOS ACE 5-HTT Gene polymorphism Pulmonary hypertension
Conflict of interests
All authors have no conflicts of interests.
- 1.Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011). Global strategy for the diagnosis, management of chronic obstructive pulmonary disease. RevisedGoogle Scholar
- 8.Kanazawa H, Okamoto T, Hirata K, Yoshikawa J (2000) Deletion polymorphisms in angiotensin converting enzyme gene gene are associated with pulmonary hypertension evokde by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162:1235–1238PubMedCrossRefGoogle Scholar
- 12.Miyahara K, Kawamoto T, Sase K, Yui Y, Toda K, Yang LX, Hattori R, Aoyama T, Yamamoto Y, Doi Y, Ogoshi S, Hashimoto K, Kawai C, Sasayama S, Shizuta Y (1994) Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur J Biochem 223:719–726PubMedCrossRefGoogle Scholar
- 16.Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF (1993) European Respiratory Society. Standardized lung function testing. Lung volumes and forced ventilatory flows. 1993 update. Eur Respir J 6:5–40Google Scholar
- 20.Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantification of left ventricle by two dimensional echocardiography. American Society of Echocardiography committee on standards, subcommitteeon quantitation of two dimensional echocardiograms. J Am Soc Echocardiogr 2:358–367PubMedGoogle Scholar
- 26.Lopez AD, Shibuya K, Rao C et al (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27:397–412Google Scholar
- 27.Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (2007) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532–555PubMedCrossRefGoogle Scholar